Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Stanford University
Stanford University
Thomas Jefferson University
Stanford University
Stanford University
UNC Lineberger Comprehensive Cancer Center
University of California, Davis
Abramson Cancer Center at Penn Medicine
Stanford University
University of California, San Francisco
University of Miami
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Queen's Medical Center
Vanderbilt-Ingram Cancer Center